Pi™ Prostate AI with expert level performance
Lucida Medical develops software to help clinicians find cancer, using AI and MRI.
Pi™ matches the accuracy of expert radiologists
The results of a major collaborative research study with 8 UK NHS hospitals, PAIR-1, have been published in the leading journal European Radiology. This study is a landmark in the development and validation of AI for prostate cancer, showing for the first time that Pi™ operates at the level of expert radiologists working in multi-disciplinary teams, across real-world, multi-centre data encompassing different MRI scanner vendors, models and field strengths.
This found that Pi™ has outstanding accuracy to detect clinically significant prostate cancer on representative, held-out validation data, with 95% sensitivity and 67% specificity. This high performance allows Pi™ to be used to help find more cancers, rule out patients who do not need further investigations, and save resources and time.
BBC film about Pi at Somerset NHS Foundation Trust
Somerset NHS Foundation Trust is the first in the UK to deploy AI to help find prostate cancer in MRI scans. After testing Pi™ with over 700 historical patient cases, they were happy that it would be safe to deploy. Pi™ is now used clinically in the Trust.
In this film originally shown on BBC Morning Live on 20 Feb 2025, Dr Elena Newby explains how they use Pi™, and we hear from a patient whose prostate cancer was detected with the help of Pi.
(Content available in the UK only.)
What clinicians say
‘Pi can identify the most clinically significant cancers and essentially allow me to offer a same day pathway to those patients. MRi in the morning, biopsy in the afternoon’
Dr Oliver Hulson
Consultant Interventional Radiologist
St James University Hospital Leeds
Case reports
Pi™ helps find a high-grade prostate cancer
Case notes:
The reporting radiologist initially thought that this man’s prostate was normal. However, reviewing the Pi™ output, they noted this lesion highlighted by AI in the apex, an area that can be easily overlooked. Biopsy found Gleason 9 high-grade prostate cancer.
Patient impact:
High-grade prostate cancer requires urgent treatment to stop it spreading. Early detection in this case should enable the man to benefit greatly from appropriate treatment.
Video – example cases
Upcoming conferences
Find out more at these events:
Get in touch, book a demo
To find out more, please contact us via this form
Latest News
Macmillan Cancer Support is investing in Lucida Medical, a spin-off from the University of Cambridge that develops Pi™ software to help radiologists find cancer
Lucida Medical Ltd announces a distribution agreement with Sectra to offer Pi AI technology to help diagnose prostate cancer
Somerset’s NHS pioneers clinical use of AI software to transform prostate cancer diagnosis
Blackford and Lucida Medical partner to enhance prostate care
Our Partners
